Mandibular metastasis of pulmonary adenocarcinoma: How unexpected could it be?

Objective: Metastatic tumours of bone must be considered in all patients with unex-plained bone pain and particularly in patients who present with a known cancer, lo-calised pain at multiple sites, and radiographic findings suggestive of metastasis. The purpose of this report was to present a case of a pathological fracture of the mandible as a consequence of metastatic pulmonary adenocarcinoma.Materials and Methods: In July 2018 a 68- year- old male patient was hospitalised because of pulmonary adenocarcinoma and attended our department for an oral maxillo- facial evaluation. He complained of pain and swelling in the right temporo-mandibular region resulting in a reported functional limitation.An Orthopantomogram (OPG) demonstrated a right intracapsular condylar compound fracture associated with an osteolytic lesion at the condyle base with jagged margins. Subsequently, a CT scan with contrast of the maxillo- facial complex and a fine- needle aspiration of the lesion was performed.Results: CT images showed the presence of a right mandibular condyle fracture as-sociated with a large osteolytic lesion which confirmed the pathological nature of the fracture. Fine- needle aspiration of the lesion confirmed its metastatic nature. It was not possible to proceed with a mandibular resection due to the critical clinical condi-tion of the patient who died in September 2018.Conclusion: Lung cancer frequently produces lytic- type metastasis, sometimes even in the jaw. In patients with an established diagnosis of lung cancer, any radiolucent lesion of the jaw or an unexplained painful symptomatology to the oro- maxillo facial complex should be placed in differential diagnosis with metastasis of the primary tumour

O Atendimento odontológico do paciente renal terminal submetido a dialise: uma revisão atual da literatura médica vigente.

Chronic renal failure is a progressive disease characterized by a gradual destruction of the nephrons and a consequent reduction in renal function. End-stage kidney disease (ESRD) requires renal replacement therapy such as peritoneal dialysis, hemodialysis or transplantation. Patients affected by ESRD or on hemodialysis are at risk of developing a series of comorbidities, including hypertension, anemia, risk of bleeding, susceptibility to infection, side effects of medications and oral manifestations associated with the disease itself and treatment on hemodialysis. In this context, oral diseases represent a potential and preventable cause of poor health outcomes in people with ESRD due to their relationship with infection, inflammation and malnutrition.A insuficiência renal crônica é uma doença progressiva caracterizada por uma destruição gradual dos néfrons e uma conseqüente redução da função renal. A doença renal em estágio terminal (DRT) requer terapia de substituição renal como diálise peritoneal, hemodiálise ou transplante. Os pacientes afetados pela DRT ou em hemodiálise correm risco de desenvolver uma série de comorbidades, incluindo hipertensão, anemia, risco de sangramento, suscetibilidade à infecção, efeitos colaterais dos medicamentos e manifestações orais associadas à própria doença e ao tratamento em hemodiálise. Nesse contexto, as doenças bucais representam uma causa potencial e evitável de maus resultados de saúde em pessoas com DRT devido à sua relação com infecção, inflamação e desnutrição

Estratificação em resina composta com a técnica da guia palatina – relato de caso

A indústria odontológica vem desenvolvendo e buscando biomateriais e técnicas que alcancem o mimetismo com a estrutura dentária. A execução de restaurações classe IV são consideradas um procedimento de média complexidade, devendo o profissional ter conhecimento de marcas comerciais, variações de matiz, croma, valor, opacidade e translucidez, podendo corrigir as imperfeições durante o procedimento. O objetivo com este trabalho foi relatar por meio de um caso clínico a utilização da guia palatina para anatomização de um dente anterior. Paciente M. R., gênero feminino, 65 anos, compareceu à Clínica Integrada I – Promoção de Saúde do Curso de Odontologia da Unoesc – Joaçaba, relatando sensibilidade no elemento dental 26, no qual possuía uma restauração de amalgama MOD, além de escurecimento no elemento 22, a qual causava desconforto estético ao sorrir. Com a realização de anamnese e exames clínico e radiográfico, constatou-se que além do escurecimento, havia a desadaptação marginal palatal da restauração pré-existente, sendo a restauração em resina composta com o uso da guia palatina, uma opção alternativa em razão de o formato estar satisfatório. O uso da guia para restaurações classe IV por meio da confecção com silicone de condensação é eficiente pois pode ser confeccionada usando como base a própria restauração pré-existente, além de reduzir o tempo clínico e facilitar a inserção de resina. Para que haja eficiência nesse tipo de confecção, o uso é exclusivo para a face palatina e parte da face incisal. O tratamento realizado foi muito eficaz, pois além de evitar maiores desgastes desnecessários na estrutura dental, reestabeleceu o sorriso e a melhora na autoestima da paciente.Palavras-chave: Biomateriais. Resinas compostas. Materiais para moldagem odontológica.

Restauração estratificada em resina composta com o uso de guia palatina em dentes anteriores

A indústria odontológica vem desenvolvendo e buscando o aprimoramento em biomateriais e técnicas para alcançar o mimetismo com a estrutura dentária. A execução de restaurações Classe IV é considerada um procedimento de média complexidade, pois há muita sensibilidade técnica em se obter cor e forma adequadas. O uso de uma guia palatina otimiza o procedimento restaurador e facilita a estratificação, obtendo-se, consequentemente, uma restauração biomimética. No presente trabalho teve-se por objetivo mostrar, por meio de um relato de caso clínico, a confecção de uma restauração anterior com o uso da guia palatina, assegurando o melhor resultado funcional e estético.Palavras-chave: Resinas compostas. Materiais para moldagem. Reabilitação

Safety and efficacy of a feed additive consisting of zeolites (≥ 50%) obtained from Neapolitan Yellow Tufa for all animal species (Italiana Zeoliti s.r.l.)

Free PMC article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10716728/Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of zeolites (≥ 50%) obtained from Neapolitan Yellow Tufa as a technological additive (functional group: anticaking) for all animal species. The additive is specified to contain not less than 50% of zeolites, namely phillipsite, chabazite and analcime. Neapolitan Yellow Tufa originates from the volcanic activity of Campi Flegrei, Italy. According to the conventional risk assessment, due to a lack of adequate data, the safety of the additive for the target species cannot be established. Based on current knowledge, there is no indication of substantial absorption of the components of the additive and, therefore, of concern for the consumer. The additive poses a risk by inhalation. It is not irritant to the skin. The Panel cannot conclude on the eye irritancy and on the dermal and respiratory sensitisation potential of the additive. As no suitable data in line with the requirements of the Guidance on risk assessment of nanomaterials were provided by the applicant, the potential risks associated with the presence of nanoparticles for the target species, the consumer and the user could not be assessed. The additive is safe for the environment. The additive is considered to be efficacious in feedingstuffs for all animal species at 20,000 mg/kg complete feed.info:eu-repo/semantics/publishedVersio

Assessment of the feed additive consisting of Enterococcus faecium DSM 7134 (Bonvital®) for chickens for fattening for the renewal of its authorisation (Lactosan GmbH & Co. KG)

[EN] Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of the additive consisting of Enterococcus faecium DSM 7134 (trade name: Bonvital®) as a zootechnical additive (gut flora stabiliser) for chickens for fattening. The additive is produced in powder and granulate (microencapsulated) forms. The applicant has provided data demonstrating that the additive currently in the market complies with the conditions of authorisation. The FEEDAP Panel confirms that the use of Bonvital® under the current authorised conditions of use is safe for the target species, the consumers and the environment. Bonvital® is not irritant to skin and eyes but should be considered a potential skin sensitiser and a respiratory sensitiser. There is no need to assess the efficacy of Bonvital® in the context of the renewal of the authorisation. The FEEDAP Panel reiterates its previous conclusions that E. faecium DSM 7134 is compatible with the coccidiostats robenidine hydrochloride, maduramicin ammonium, diclazuril, decoquinate, halofuginone hydrobromide, monensin sodium and lasalocid A sodiumSIThe Panel wishes to acknowledge the contribution of Yolanda Garc ıa Cazorla and Joana Revez to this opinio

Assessment of the feed additive consisting of Lactiplantibacillus plantarum (formerly Lactobacillus plantarum) DSM 12836 for all animal species for the renewal of its authorisation (Lactosan GmbH & Co KG)

[EN] Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of Lactiplantibacillus plantarum (formerly Lactobacillus plantarum) DSM 12836, as a technological additive for all animal species. The applicant has provided evidence that the additive currently in the market complies with the existing conditions of authorisation. There was no new evidence that would lead the FEEDAP Panel to reconsider its previous conclusions. Thus, the Panel concluded that the additive remains safe for all animal species, consumer and the environment under the authorised conditions of use. The additive was not irritant to skin and eyes but is considered a skin and respiratory sensitiser. The present application for renewal of the authorisation did not include a proposal for amending or supplementing the conditions of the original authorisation that would have an impact on the efficacy of the additive. Therefore, there was no need for assessing the efficacy of the additive in the context of the renewal of the authorisationSIThe Panel wishes to acknowledge the contribution of Yolanda García Cazorla to this opinio

Assessment of the feed additive consisting of endo‐1,4‐β‐xylanase produced by Trichoderma reesei CBS 114044 (ECONASE® XT) for piglets (weaned), chickens reared for laying, chickens for fattening, turkeys for fattening and turkeys reared for breeding for the renewal of its authorisation (Roal Oy)

[EN] Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the ECONASE® XT, an enzyme based on endo-1,4-β-xylanase produced by a genetically modified strain of Trichoderma reesei CBS 114044. The additive is currently authorised for use in chickens for fattening, chickens reared for laying, laying hens, turkeys for fattening, turkeys reared for breeding, minor poultry species, piglets (weaned) and pigs for fattening. ECONASE® XT is currently authorised in two forms, a solid and a liquid form with activities of 4,000,000 and 400,000 BXU/g, respectively. In a previous opinion, the FEEDAP Panel could not exclude the potential presence of recombinant DNA derived from the production organism in recent batches of the additive. The applicant has submitted data to support the absence of recombinant DNA derived from the production organism in recent product batches. The FEEDAP Panel confirms that the data provided support the absence of recombinant DNA of Trichoderma reesei CBS 114044 in the additive and thus, no safety concern was identified.SIThe Panel wishes to acknowledge the contribution of Angelica Amaduzzi and Yolanda García Cazorla to this opinion

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

The feed additive Monteban\uae G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60\u201370 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for antimicrobial resistance in Streptomyces spp. under assessment. Based on the available data set, the FEEDAP Panel cannot conclude on the safety of Monteban\uae G100 for chickens for fattening. The simultaneous use of Monteban\uae G100 and certain antibiotic drugs (e.g. tiamulin) is contraindicated. Narasin is not genotoxic. No indication of carcinogenicity or developmental toxicity was found at the doses tested in the mouse, rat and rabbit. The lowest no observed effect level (NOEL) identified in the oral toxicity studies was 0.5 mg/kg body weight (bw) per day for the neuropathy seen in a one-year dog study. The acceptable daily intake (ADI) derived from this NOEL is 0.005 mg narasin/kg bw applying a uncertainty factor of 100. Monteban\uae G100 is safe for the consumer. Maximum residue limits (MRLs) of 50 lg narasin/kg for all wet tissues ensure consumer safety. Monteban\uae G100 is irritatant to the eyes but not to the skin. It has the potential to induce skin sensitisation. Inhalation exposure would pose a risk to persons handling the additive. Narasin, when used as a feed additive for chickens for fattening at 70 mg/kg feed, is not expected to pose a risk to the environment. The risk for sediment compartment cannot be assessed. The FEEDAP Panel cannot conclude on the efficacy of Monteban\uae at the minimum applied dose of 60 mg narasin/kg complete feed for chickens for fattening